Biblio
TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases. Am J Hematol. 2021.
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. Expert Opin Pharmacother. 2019:1-10.
Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review. J Immunol Res. 2015;2015:968212.
.